These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38056198)

  • 1. Effect of rituximab in patients with PLA2R-associated membranous nephropathy and malignancy.
    Guo Y; Ren M; Wang Y; Zhai Z; Yu L; Wang L; Tang L
    Int Immunopharmacol; 2024 Jan; 126():111327. PubMed ID: 38056198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach.
    Wang S; Deng Z; Wang Y; Bao W; Zhou S; Cui Z; Zheng D
    BMC Nephrol; 2023 May; 24(1):146. PubMed ID: 37237260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy.
    Ruggenenti P; Debiec H; Ruggiero B; Chianca A; Pellé T; Gaspari F; Suardi F; Gagliardini E; Orisio S; Benigni A; Ronco P; Remuzzi G
    J Am Soc Nephrol; 2015 Oct; 26(10):2545-58. PubMed ID: 25804280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of Rituximab, Low-Dose Cyclophosphamide, and Prednisone for Primary Membranous Nephropathy: A Case Series With Extended Follow Up.
    Zonozi R; Laliberte K; Huizenga NR; Rosenthal JK; Jeyabalan A; Collins AB; Cortazar FB; Niles JL
    Am J Kidney Dis; 2021 Dec; 78(6):793-803. PubMed ID: 34174365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab in patients with membranous nephropathy and kidney insufficiency.
    Guo Y; Wang L; Wang Y; Li X; Zhai Z; Yu L; Liang Y; Liu P; Tang L
    Front Pharmacol; 2022; 13():1002117. PubMed ID: 36299887
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and safety of rituximab in patients with PLA2R associated membranous nephropathy and resolved HCV infection.
    Li X; Song D; Hao Y; Ren M; Guo Y; Zhao H; Wang Y; Tang L
    Sci Rep; 2024 Sep; 14(1):20981. PubMed ID: 39251782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparison of efficacy and safety of immunosuppressive therapy and rituximab targeting therapy in idiopathic membranous nephropathy].
    Zhao R; Fan R; Pan Y; Guo Y; Han Y; Wang Y; Zhang J; Yang H; Yu D; Chen W
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2024 Jul; 40(7):636-641. PubMed ID: 39179407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of long-term repeated rituximab treatment in refractory phospholipase A2 receptor-antibody-related membranous nephropathy.
    Zhang L; Chen M; Le W; Zhang M; Tu Y; Zuo K; Chen D; Wu Y; Li S; Zeng C; Cheng Z; Xie H
    Immunotherapy; 2022 Oct; 14(15):1237-1244. PubMed ID: 36097696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PLA2R-IgG4 antibody as a predictive biomarker of treatment effectiveness and prognostic evaluation in patients with idiopathic membranous nephropathy: a retrospective study.
    Huang Y; Zhou J; Zhou K; Huang B; Xue J; Zhang X; Liu B; Zhang Z; Zhou L; Cai T; Zhang Y; Hu Z; Wang L; Liu X
    PeerJ; 2022; 10():e14193. PubMed ID: 36248712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value of the domain specific PLA2R antibodies for clinical remission in patients with primary membranous nephropathy: A retrospective study.
    Zhou K; Zhou J; Zhou L; Xue J; Liu B; Zhang Z; Zhang X; Cai T; Shao S; Huang B; Zhang Y; Hu Z; Wang L; Liu X
    PLoS One; 2024; 19(5):e0302100. PubMed ID: 38718066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological Characteristics and Outcomes of PLA
    Luo J; Yuan Y; Tian J; Zhou Z; Su C; Yang F; Wang G
    Am J Kidney Dis; 2022 Sep; 80(3):364-372. PubMed ID: 35288217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Long-term efficacy of low-dose rituximab treatment in patients with primary membranous nephropathy].
    Qi Y; Jia JY; Gu QH; Zheng ZF; Li LN; Li D; Jia ZH; Xue Y; Yan TK
    Zhonghua Yi Xue Za Zhi; 2022 Nov; 102(40):3201-3206. PubMed ID: 36319174
    [No Abstract]   [Full Text] [Related]  

  • 13. Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy.
    Hoxha E; Thiele I; Zahner G; Panzer U; Harendza S; Stahl RA
    J Am Soc Nephrol; 2014 Jun; 25(6):1357-66. PubMed ID: 24610926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Negative anti-phospholipase A2 receptor antibody status at three months predicts remission in primary membranous nephropathy.
    Stefan G; Stancu S; Zugravu A; Popa O; Zubidat D; Petre N; Mircescu G
    Ren Fail; 2022 Dec; 44(1):258-268. PubMed ID: 35172682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of rituximab for primary membranous nephropathy with different clinical presentations: a retrospective study.
    Zhang S; Huang J; Dong J; Li Z; Sun M; Sun Y; Chen B
    Front Immunol; 2023; 14():1156470. PubMed ID: 37187749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of serum mannose-binding lectin, anti-phospholipase A2 receptor antibody and renal outcomes in idiopathic membranous nephropathy and atypical membranous nephropathy: a single center retrospective cohort study.
    Zhao Y; Cai M; Jiang Z; Dong B; Yan Y; Wang Y; Zuo L
    Ren Fail; 2022 Dec; 44(1):428-433. PubMed ID: 35272568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment resistant M-type phospholipase A2 receptor associated membranous nephropathy responds to obinutuzumab: a report of two cases.
    Hudson R; Rawlings C; Mon SY; Jefferis J; John GT
    BMC Nephrol; 2022 Apr; 23(1):134. PubMed ID: 35392837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of leflunomide combined with prednisone for the treatment of PLA2R-associated primary membranous nephropathy.
    Guo Y; Wu X; Liu L; Zhang H; Yang L; Chen W
    Ren Fail; 2020 Nov; 42(1):122-130. PubMed ID: 31957527
    [No Abstract]   [Full Text] [Related]  

  • 19. Circulating anti-phospholipase A2 receptor antibodies as a diagnostic and prognostic marker in Greek patients with idiopathic membranous nephropathy - a retrospective cohort study.
    Provatopoulou S; Kalavrizioti D; Stangou M; Kouri MN; Kalliakmani P; Papasotiriou M; Papachristou E; Goumenos DS; Papagianni A
    Rom J Intern Med; 2019 Jun; 57(2):141-150. PubMed ID: 30864406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of rituximab and short-term glucocorticoids in the treatment of anti-phospholipase A
    Ma Q; Li M; Xu G
    Clin Exp Med; 2023 Dec; 23(8):5337-5343. PubMed ID: 37688683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.